AI-generated summary
The authors report a pre-post pilot study of 50 patients with type II diabetes and diabetic peripheral neuropathy who received low level laser therapy on the feet for 10 days. They report that serum neuron specific enolase levels fell significantly after four weeks in 42 patients, along with reduced vibration perception threshold and pain scores. The authors note that larger trials are needed to investigate these findings.
- Participants
- 50
- Who or what was studied
- Patients with type II diabetes mellitus and diabetic peripheral neuropathy
- Limits stated in the abstract
- This is a small pilot study with a pre-post design and no control group, and the authors state that larger trials are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Neuropathy, Photobiomodulation, Pilot study, Low-level laser therapy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.